ITCIライブシグナル | Getagraph.comで利益を最大化

買う 174 min ago

@ $72.40

発行日: 29 4月 2024 @ 22:52

リターン: 1.44%

前回のシグナル: 4月 27 - 04:57

前回のシグナル: 売る

リターン: -1.13 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Stats
本日の出来高	167 042
平均出来高	961 964
時価総額	7.11B
EPS	$0 ( 2024-02-22 )
次の収益日	( $-0.330 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-50.30
ATR14	$1.800 (2.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Mates Sharon	Buy	11 382	Common Stock
2024-04-24	Mates Sharon	Buy	8 638	Common Stock
2024-04-24	Mates Sharon	Sell	11 382	Stock Option (right to buy)
2024-04-24	Mates Sharon	Sell	8 638	Stock Option (right to buy)
2024-03-31	Van Nostrand Robert L	Buy	79	Common Stock

INSIDER POWER
1.82
Last 100 transactions
Buy: 523 032 \| Sell: 503 157

ボリューム相関

長: 0.69 (moderate)

短: -0.78 (moderate negative)

Signal:(52) Neutral

Intra-Cellular Therapies 相関

10 最も正の相関
BOCH	0.927
SHSP	0.882
BLRX	0.862
SOVO	0.851
DBDR	0.84
MMAC	0.838
GWAC	0.833
SCYX	0.825
FCAC	0.823
TLSA	0.823

10 最も負の相関
GAINL	-0.944
APOP	-0.87
RMRM	-0.867
TDAC	-0.855
ISNS	-0.852
FNWD	-0.85
CLDX	-0.836
MNDO	-0.835
SVOK	-0.835
AGIL	-0.83

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Intra-Cellular Therapies 相関 - 通貨/商品

-0.18
( neutral )

0.53
( weak )

0.00
( neutral )

0.09
( neutral )

-0.31
( neutral )

0.35
( neutral )

Intra-Cellular Therapies 財務諸表

Annual	2023
収益:	$462.18M
総利益:	$428.43M (92.70 %)
EPS:	$-1.460

FY	2023
収益:	$462.18M
総利益:	$428.43M (92.70 %)
EPS:	$-1.460

FY	2022
収益:	$249.13M
総利益:	$228.69M (91.79 %)
EPS:	$-2.72

FY	2021
収益:	$83.80M
総利益:	$75.77M (90.41 %)
EPS:	$-3.50

Financial Reports:

No articles found.

Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

リアルタイムの更新： Intra-Cellular Therapies [ITCI]

Upcoming Earnings Alert